admin – Page 18 – Swanson Reed | Specialist R&D Tax Advisors

Pioneering Collaborative Research and Development for Healthcare Innovation

In an era where healthcare innovation is paramount, Nature’s Toolbox, Inc. (NTx) has landed another federally funded contract under a government vaccine production program. The contract will see the Rio Rancho-based life sciences startup collaborate with Houston Methodist Hospital and BARDA (Biomedical Advanced Research and Development Authority).

NTx, a prominent player in the field of biotechnology, has recently joined forces with Houston Methodist Hospital, one of the leading medical institutions in the nation, and BARDA, a division of the U.S. Department of Health and Human Services responsible for developing and procuring advanced medical solutions. Together, they are embarking on a journey of research and development that holds the promise of transformative breakthroughs.

At the heart of this partnership lies the pursuit of innovative medical solutions that can tackle some of the most pressing healthcare challenges of our time. As we confront global health crises and increasingly complex medical conditions, the need for cutting-edge therapies and treatments has never been more critical.

NTx, with its deep expertise in biotechnology, is well-positioned to contribute groundbreaking solutions to the collaboration. Their commitment to advancing medical science and improving patient outcomes aligns seamlessly with the missions of Houston Methodist Hospital and BARDA.

While the specific projects and research directions are yet to be disclosed, the collective aim of this partnership is clear: to harness the power of science and technology to enhance our capacity to respond to health emergencies, accelerate the development of life-saving treatments, and ensure a brighter and healthier future for all.

In an era where scientific collaboration is the cornerstone of progress, NTx, Houston Methodist Hospital, and BARDA are setting a shining example of how cooperation between experts in different fields can yield remarkable results. Their commitment to pushing the boundaries of what is possible in healthcare research and development offers a glimpse into the exciting possibilities that lie ahead.

As the partnership unfolds, it is bound to capture the attention of the healthcare community and the world at large. NTx’s dedication to pioneering research and development, coupled with the resources and expertise of Houston Methodist Hospital and BARDA, paints a promising picture of a future where medical innovation knows no bounds.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Revolutionizing Healthcare: Inbound Health Secures $30M in Series B Funding

Home Hospital Newco, Inc. (DBA Inbound Health), a Minneapolis-based company that facilitates acute and post-acute care in the comfort of patients’ homes, has recently announced a successful $30 million Series B funding round. Leading this investment is HealthQuest Capital, with continued support from existing investors Flare Capital Partners and McKesson Ventures.

In a healthcare landscape where the home is increasingly becoming a focal point for care, Inbound Health is at the forefront of enabling health systems to provide advanced care services outside of traditional clinical settings. The programs powered by Inbound Health are not just innovative; they are yielding remarkable clinical, operational, and financial benefits for partnering health systems.

One of the most crucial aspects of these advanced care-at-home models is their ability to reduce healthcare costs significantly. By lowering the length of hospital stays, readmission rates, and avoidable complication rates (such as infections and delirium), Inbound Health is aligning economic interests with health system partners through a value-based care approach.

Dave Kerwar, CEO of Inbound Health, expressed his excitement about this funding, stating, “In partnership with leading health systems around the country, we are committed to advancing our clinical, operating, and technology assets to scale high-quality, advanced care in the home.”

The Series B financing will support Inbound Health’s expansion into new markets, further development of clinical programs, and the evolution of its proprietary technology and advanced analytics platform. The company will also continue to build customized operating assets, focusing on supply chain optimization, labor management, and logistics.

What sets Inbound Health apart is its comprehensive platform, which includes all the necessary capabilities to deliver home-based advanced care at scale. This encompasses clinical expertise, technology solutions, managed care services, supply chain partnerships, and labor management.

Garheng Kong, Managing Partner at HealthQuest Capital, highlighted the significance of Inbound Health’s innovative solution. He said, “Inbound Health’s innovative solution addresses a pressing need within our healthcare system by enabling patients to receive high-quality care in the comfort of their homes, thereby enhancing the overall patient experience and creating a solution that benefits all stakeholders.”

With a flexible partnership structure, Inbound Health empowers its customers to leverage their existing assets and capabilities while relying on the company to bridge the gaps required to scale these revolutionary programs across their service areas.

To date, Inbound Health has positively impacted over 4,200 patients with 185 primary diagnoses, particularly through its operational partnership with Allina Health since May 2020. The program integrates biometric monitoring, digital surveillance, in-home nursing and therapy, virtual visits, and a comprehensive supply chain to deliver safe, high-quality care.

Inbound Health’s mission to transform healthcare by delivering exceptional care directly to patients’ homes continues to gain momentum, and this latest funding round is a testament to the company’s dedication to reshaping the future of healthcare delivery.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Empowering Data Ownership: 360ofme Raises Seed Funding for Ethical Data Exchange Platform

Detroit-based 360ofme, Inc. has recently raised an undisclosed amount of seed funding, marking a significant milestone in the development of their groundbreaking ethical data exchange platform. The undisclosed amount of funding comes from a consortium of backers including Invest Detroit, Michigan Rise, and Ann Arbor Spark, demonstrating strong support for the company’s mission.

Led by Founder and CEO Cindy Warner, 360ofme is pioneering an ethical data exchange platform that empowers individuals to take control of their digital lives. This innovative platform is built on a foundation of low-code, secure, and compliant technology, setting new standards for data sharing, learning, and monetization while prioritizing user privacy.

At its core, 360ofme acts as a privacy guardian, overseeing data collection, consent management, and compliance with world-class privacy standards. This ensures that users can securely share their data with businesses, family members, doctors, and other trusted individuals of their choice. The platform covers a broad spectrum of digital life aspects, from healthcare and finance to insurance, automotive, and home.

One of the platform’s standout features is its utilization of artificial intelligence (AI), which unlocks powerful insights from users’ digital footprints. This means that individuals can gain valuable knowledge from their own data, helping them make informed decisions and better understand their digital lives.

The recent Seed funding injection will play a pivotal role in accelerating 360ofme’s product development, facilitating the hiring of top talent, and paving the way for a successful commercial launch. Notably, the company is expanding its team with the addition of two key executives: Kara Grasso, who joins as Head of Strategy and Revenue, and Philippe Le Berre, the new Chief Technology Officer. Their expertise will undoubtedly contribute to the platform’s continued growth and innovation.

360ofme’s ethical data exchange platform is a game-changer in the era of data privacy and ownership. By putting individuals in control of their data and providing AI-driven insights, it empowers users to harness the full potential of their digital lives. With strong financial backing and a dedicated team, 360ofme is poised to revolutionize the way we interact with and manage our digital information.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Space Tango’s New CEO Charts a Course for Groundbreaking Research and Development in Space

Space Tango, the pioneering Kentucky-based startup renowned for conducting innovative research and science experiments on the International Space Station (ISS), recently announced Sita Sonty as their new Chief Executive Officer (CEO), heralding a new era of leadership and innovation for the company.

Sonty brings a wealth of experience to her role, having previously led the space industry practice at the Boston Consulting Group and served as the Head of Human Spaceflight Sales at SpaceX. Her appointment signifies Space Tango’s commitment to advancing microgravity applications in diverse fields, including hardware, software, materials science, biotechnology, and medicine.

Co-founder Twyman Clements, who has been at the helm, will continue to play a pivotal role in the company as President, providing valuable continuity and expertise. Under Sonty’s leadership, Space Tango aims to expand its business, leveraging its “proven flight payload heritage, a dedicated customer base, and cutting-edge commercial use cases.” These endeavors hold the potential to revolutionize medicine and additive manufacturing in the unique environment of space.

Founded in 2014, Space Tango emerged from a partnership between Twyman Clements and Kris Kimel, the former CEO of the Kentucky Science and Technology Corporation. Their shared vision was to simplify and enhance access to space-based research and product development. Today, the company stands as a commercial spinoff of Kentucky Space, a nonprofit consortium comprising universities and public and private organizations, with a presence in Kentucky, Texas, Florida, California, and Washington, D.C.

Through a NASA Space Act Agreement, Space Tango has been providing state-of-the-art facilities on the ISS since 2017 to support research and development as well as manufacturing. Their mission centers on harnessing the microgravity environment as a new frontier for discovery and innovation.

Space Tango envisions a future where groundbreaking advancements in healthcare and technology emerge from space-based research, and they are committed to creating a global market 250 miles above Earth’s surface. By collaborating with diverse industry and educational partners, Space Tango seeks to improve life on Earth and inspire future generations to explore the limitless possibilities of space.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

IRS Seeking Feedback on New R&D Tax Credit Form

bigstock Smiling business people in mee 96690950 e1457318169602

The IRS recently released their proposed changes to the Form 6765, Credit for Increasing Research Activities. The form is used by taxpayers to claim the research and development tax credit.

By unveiling the new version of the form, the company is hoping to gain feedback from stakeholders in advance of the formal draft release process for form changes. Some of the proposed changes address previous feedback the agency received from taxpayers and tax professionals, said the IRS, which added that it would like to make the changes effective beginning with tax year 2024.

Ultimately, their goal is to provide a uniform, consistent, and predefined format for taxpayers to streamline the process of reporting details about the tax credit. Not only will this provide clearer guidance for taxpayers, it will help the IRS to manage research credit issues and resources in the most effective and efficient manner possible.

The proposed changes to Form 6765 include:

A new Section E with five questions seeking miscellaneous information.
A new Section F for reporting quantitative and qualitative information for each business component, required under Section 41 of the Internal Revenue Code.
Moving the “reduced credit” election question and the “controlled groups or businesses under common control” question from line 17 and line 34 to the top of Form 6765.

The IRS is also requesting feedback on whether Section F should be optional for certain taxpayers, including those:

With qualified research expenditures less than a certain dollar amount at a controlled group level;
With an R&D credit less than a certain dollar amount at a controlled group level; or
That are a qualified small business for the payroll tax credit.

Feedback for each suggestion should address the justification, limitation amounts, and pros and cons, the IRS said.

If Section F were optional for certain taxpayers, the IRS said it would not affect the requirement to maintain books and records and to provide Section F information in similar format, if requested. Also, it would not apply to amended returns for the R&D credit.

All feedback on the proposed form changes, potential Section F options, and all other questions should be submitted to Lbi.rt.team@irs.gov with the subject line: “Feedback/Questions F6765.” All feedback is requested by Oct. 31 and will be considered before the IRS finalizes any Form 6765 changes, the agency said.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Vivante Health’s Secures $31M to Transform Digestive Health with Novel Platform

South Carolina Patent of the Month - June 2021

Vivante Health recently announced a remarkable achievement in securing a $31 million Series B funding round, led by the Mercato Partners. This infusion of capital has propelled Vivante Health’s total funding to an impressive $47 million, reflecting the immense promise and potential of their innovative approach to gastrointestinal (GI) health.

At the core of Vivante Health’s offering is their cutting-edge platform known as GIThrive, a digital solution designed to provide personalized care plans for individuals grappling with digestive disorders. GIThrive empowers patients to take charge of their health by enabling them to track symptoms, access educational content, and engage with self-guided behavioral health modules. What sets GIThrive apart is its integrated care team, which includes dietitians, coaches, and healthcare physicians, all readily accessible through the platform.

The Illinois-based company’s recent funding success will be channeled into enhancing their technology and expanding their workforce, reaffirming their commitment to advancing GI health solutions. Bill Snyder, CEO of Vivante Health, articulated the company’s vision, stating, “One in four Americans suffers from a digestive disorder or undiagnosed digestive symptoms that affect their quality of life as well as their healthcare costs. We have proven that our scalable technology platform paired with our comprehensive care team results in better health, lower costs and a much better experience for the members we serve.”

Vivante Health’s remarkable journey of research and development has garnered significant attention and investment, with prior funding rounds including a $16 million Series A round in the previous year, a $5.8 million Series A1 investment in 2020, and a $6 million investment in 2018.

Their partnership with Solera Health, a digital platform specializing in benefits and chronic disease management programs, underscores the growing recognition of Vivante’s pioneering role in the field. As Vivante Health continues to make strides in digestive health, their all-in-one digital program, GIThrive, is poised to empower millions of individuals to reclaim their lives from digestive symptoms while significantly reducing healthcare costs for employers and health plans.

Vivante Health’s mission to tackle digestive diseases head-on is a testament to their dedication to improving the lives of millions and reshaping the landscape of GI health. With their innovative solutions, they offer hope and relief to those affected by digestive disorders, promising a brighter and healthier future for all.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

KORE Power’s Innovative Research and Development Fuels Sustainable Energy Solutions

KORE Power, Inc., a pioneering force in the clean energy industry, has announced a recent multi-year offtake agreement and collaboration with Nidec North America. This agreement is a testament to their commitment to advancing power technologies and promoting sustainable energy solutions.

Under this groundbreaking agreement, KORE Power is set to deliver between 450 MWh and 600 MWh of cutting-edge lithium-ion battery cells, modules, and racks to Nidec North America in 2024, with the potential to scale up to an impressive 2.2 GWh by 2026. This partnership solidifies KORE’s position as a leading supplier in the energy storage and power conversion systems sector.

The collaboration goes beyond mere supply agreements; it’s a strategic partnership aimed at developing turnkey energy storage systems for both utility-scale and commercial/industrial projects. KORE’s DC Blocks and Nidec’s Power Conversion Systems (PCS) are at the forefront of this innovative venture, promising efficient, durable, and high-density solutions that can seamlessly integrate into challenging electricity grids.

KORE Power is making ambitious strides in lithium-ion battery technology by committing to deliver 450 MWh to 2.2 GWh of battery cells, modules, and racks within the next three years. This aligns perfectly with Nidec’s commitment to supplying 225 MVA to 1,100 MVA of power conversion systems, all to meet the surging demand in North America’s energy storage market.

The significance of this partnership is echoed by Lindsay Gorrill, CEO and Founder of KORE Power, who highlighted the century of combined experience that both companies bring to the table. They are united in their mission to drive energy storage solutions forward for industrial, commercial, and utility-scale customers.

Dominique Llonch, President of Nidec Industrial Solutions, emphasized the importance of addressing the growing demand for energy storage projects and maximizing returns on intermittent energy sources. Together, these companies are poised to deliver innovative solutions that cater to the ever-evolving energy landscape.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

OVO Venture Partners Leads $5M Seed Round in Climate-Tech Innovator Kind Designs

In an exciting development, GOVO Venture Partners, alongside M4 Investing and the Florida Opportunity Fund, is spearheading a groundbreaking $5 million seed investment round in Miami-based Kind Designs. This strategic move marks GOVO’s third portfolio company investment since the launch of its venture fund, GOVO Fund I, earlier this year in January.

Kind Designs, a climate-tech startup, is at the forefront of eco-friendly innovation, focusing on the production of 3D-printed seawalls designed to safeguard coastal communities against the rising sea levels. Utilizing proprietary technology, Kind Designs creates Living Seawalls™️ that emulate the natural structures of coral reefs and mangroves. These Living Seawalls not only provide vital protection but also serve as biodiversity hotspots, improving water quality. They are equipped with embedded sensors to collect water quality data and actively sequester carbon.

GOVO Venture Partners, headquartered in Winter Park, Florida, specializes in early-stage investments from seed rounds through series A, with a particular focus on companies where government interaction or navigating government regulations plays a pivotal role in their success.

M4 Investing, a Florida-based family office with a diverse portfolio of companies and investments in real estate, private equity funds, and venture capital, is also a key player in this endeavor.

This collaboration promises to drive forward novel solutions for climate resilience and sets a new standard for eco-conscious innovation in coastal protection. Stay tuned for the positive impact Kind Designs will make in coastal cities worldwide.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

GTL Americas and Hyundai ENG America Partner for $3.5 Billion Green Fuel Project

ClearFlame Engine Technologies Receives Funding to test Clean Diesel-style Fuel

GTL Americas (GTLA) is set to embark on a groundbreaking $3.5 billion industrial project in Jefferson County, Arkansas. The company’s ambitious endeavor is to produce 1.7 million gallons of environmentally-friendly motor fuel daily, a significant milestone in the renewable energy sector. In this exciting venture, GTLA has joined forces with Hyundai ENG America, Inc. (Hyundai) for the construction of a colossal facility sprawled across an 1,800-acre site, located just 13 miles north of Pine Bluff.

The project, slated to commence within the next 18 months, is anticipated to unfold in four phases and could reach completion by 2029. It’s worth noting that this project holds the distinction of being the largest industrial initiative in the history of Arkansas and is set to employ approximately 225 workers, with the potential for further cost escalation as it progresses.

The GTLA project in Jefferson County represents a significant leap towards sustainability, as it will convert natural gas into 1.7 million gallons of ultra-clean transportation fuels daily. Additionally, it will generate 150 MW of carbon-free steam-generated electricity. Notably, the construction phase and commissioning period alone will create an estimated 2,500 jobs.

GTLA’s vision is to establish Arkansas as the nation’s premier producer of ultra-clean, high-grade diesel, naphtha, and even jet fuel. Hyundai and S&B Engineers and Constructors, Ltd. (S&B) are collaborating to deliver the Front-End Engineering Design (FEED) and Engineering, Procurement, Construction, and Commissioning (EPCC) phases of this historic industrial project.

Upon completion, this facility will be the only one of its kind in the United States, further cementing GTL Americas’ position as a pioneer in sustainable energy solutions. The project is backed by Energy Security Partners, Hanwha Petrochemicals from Korea, and the Arkansas Teachers Retirement Funds.

The distribution of these clean fuels will encompass various modes of transportation, including trucks, rails, and marine barges, with the added capability of connecting to product pipelines, supplying customers regionally and across the U.S. and international markets.

Arkansas was chosen as the ideal location for this facility due to its strategic advantages: it lies outside the hurricane zone, boasts excellent access to railroads, interstate highways, airports, and its central geographic location in the country.

GTL Americas, headquartered in Little Rock, Arkansas, is spearheading a remarkable gas-to-liquids (GTL) project with a daily capacity of 33,000 barrels. This cutting-edge plant will utilize the Fischer-Tropsch (FT) technology to transform pipeline natural gas into clean liquid transportation fuels and specialty chemicals. With a construction workforce of over 2,500 and around 250 permanent employees, this world-class project is poised to redefine the energy landscape in Arkansas and beyond.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Unlocking the Future of Healthcare: Gero’s Epigenetic Biomarker Discovery

Gero, a biotechnology startup, has recently announced a partnership with FOXO Technologies. FOXO is the creator of a saliva-based epigenetic technology while Gero is creating therapeutics against chronic diseases with a mission to slow down human aging itself.

Epigenetic biomarkers are a hot topic in the world of medical research, and Gero is harnessing their potential to transform healthcare. These biomarkers provide a window into the way genes are regulated and can offer crucial insights into various aspects of health, from disease risk to aging.

The companies have not yet signed a letter of intent, but “a deal will happen,” Gero CEO Peter Fedichev said. The scientific, technical, and financial details are still being worked out.

Gero’s partnership with FOXO Technologies could be a game-changer. FOXO proteins play a crucial role in regulating genes associated with longevity and age-related diseases. By leveraging FOXO technologies, Gero aims to uncover a treasure trove of epigenetic biomarkers that could reshape healthcare as we know it.

Aging is a complex process, and Gero’s efforts are dedicated to unraveling its mysteries. By understanding the epigenetic changes that occur as we age, Gero seeks to develop innovative therapies and interventions that promote healthy aging and extend our lifespan.

One of the most exciting aspects of Gero’s work is its potential for precision medicine. Epigenetic biomarkers can help tailor treatments to individual patients, ensuring they receive the right care at the right time. This personalized approach has the potential to revolutionize how we treat and prevent diseases.

As Gero advances its epigenetic biomarker discovery through FOXO Technologies, the possibilities for the future of healthcare are endless. Imagine a world where diseases are detected and treated before they even manifest symptoms, where aging is a graceful process, and where each individual’s health journey is unique.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.